Watch for Medivation to Potentially Rebound After Falling 4.71% Yesterday
Comtex SmarTrend(R) - Tue Dec 23, 4:39PM CST
Medivation (NASDAQ:MDVN) traded in a range yesterday that spanned from a low of $96.55 to a high of $103.02. Yesterday, the shares fell 4.7%, which took the trading range below the 3-day low of $102.39 on volume of 1.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
MDVN: 99.23 (+1.23)
Medivation Licenses CureTech's Cancer Drug Pidilizumab - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 23, 3:30PM CST
Medivation (MDVN) exercised its option for pidilizumab (CT-011) from CureTech, Ltd. under the terms of the license agreement entered into on Oct 23, 2014.
MDVN: 99.23 (+1.23), MRK: 57.46 (+0.25), AMGN: 160.67 (+3.15), BMY: 59.15 (-0.01)
Medivation (MDVN): Today's Weak On High Volume Stock
at The Street - Tue Dec 23, 9:03AM CST
Trade-Ideas LLC identified Medivation (MDVN) as a weak on high relative volume candidate
MDVN: 99.23 (+1.23)
Pre-Market Scans on Biotech Stocks - Sarepta Therapeutics, Medivation, Alexion Pharma, Alkermes, and Cepheid
PR Newswire - Tue Dec 23, 7:50AM CST
Investor-Edge has initiated coverage on the following equities: Sarepta Therapeutics Inc. (NASDAQ: SRPT), Medivation Inc. (NASDAQ: MDVN), Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), Alkermes PLC (NASDAQ: ALKS), and Cepheid (NASDAQ: CPHD). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Monday, December 22, 2014, the NASDAQ Composite ended at 4,781.42, up 0.34%, the Dow Jones Industrial Average advanced 0.87%, to finish the day at 17,959.44, and the S&P 500 closed at 2,078.54, up 0.38%. The gains were broad based as eight out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 807.53, down 1.15%, while the index has advanced 8.06% in the previous three months. Register for your complimentary reports on these five stocks at:
MDVN: 99.23 (+1.23), SRPT: 13.88 (+0.47), CPHD: 53.39 (+0.51), ALXN: 181.96 (+3.09), ALKS: 56.16 (+1.02)
Medivation exercises license to pidilizumab from CureTech
M2 - Tue Dec 23, 5:22AM CST
Biopharmaceutical company Medivation (NASDAQ:MDVN) said on Monday that it has exercised its option to license pidilizumab (CT-011) from CureTech.
MDVN: 99.23 (+1.23)
Medivation exercises option for PD-1 inhibitor
Seeking Alpha - at Seeking Alpha - Mon Dec 22, 3:38PM CST
MDVN: 99.23 (+1.23)
Medivation Exercises License Option for Pidilizumab
Marketwired - Mon Dec 22, 3:10PM CST
Medivation, Inc. (NASDAQ: MDVN) today announced that it has exercised its option under the terms of the license agreement announced on October 23, 2014, for pidilizumab (CT-011), an immune modulatory anti-PD-1 monoclonal antibody from CureTech, Ltd. Under the license agreement, Medivation will be responsible for all development, regulatory and commercialization activities for pidilizumab for all indications, including oncology.
MDVN: 99.23 (+1.23)
The Most Disappointing Clinical Failures in 2014
Motley Fool Staff - Motley Fool - Sun Dec 21, 6:32PM CST
Since roughly 90% of all clinical trials end in a failure, it isn't too shocking that 2014 boasted its fair share of clinical trial disappointments. But while failure is common and expected in the industry, some defeats were more disappointing than...
MDVN: 99.23 (+1.23), JNJ: 104.59 (+0.31), AZN: 70.44 (+0.26), PFE: 31.42 (-0.03), AMGN: 160.67 (+3.15), GSK: 42.85 (+0.11), EXEL: 1.29 (-0.01)
3 Large Cap Biotech Stocks That Could Surprise Investors in 2015
Todd Campbell, The Motley Fool - Motley Fool - Sun Dec 21, 11:55AM CST
Source: Celgene Corp. The volatility that comes with investing in biotech stocks can test the patience of even the most risk-tolerant investor. Many investors may be better served focusing on companies with proven track records of success rather...
MDVN: 99.23 (+1.23), JNJ: 104.59 (+0.31), BIIB: 340.89 (+5.13), CELG: 109.60 (+3.48)
These Biotech Stocks Are Growing Even Faster Than Gilead Sciences
Todd Campbell, The Motley Fool - Motley Fool - Sun Dec 21, 7:31AM CST
Thanks to billions of dollars in new revenue from recently launched hepatitis C drugs, Gilead Sciences sales surged 117% year over year during the third quarter. That's impressive growth by any measure, but investors might be surprised to learn...
MDVN: 99.23 (+1.23), JNJ: 104.59 (+0.31), PCYC: 121.84 (+1.15), GILD: 91.29 (+1.84)
Seeking Alpha's Biotech Weekly: A Merck Purchase, Spectacular Auspex, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Dec 19, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. What should the Seeking Alpha community be reading and writing about? Please leave...
SPHS: 0.46 (+0.02), ASPX: 49.93 (-0.10), MDVN: 99.23 (+1.23), CYCC: 0.69 (+0.01), OPK: 9.63 (+0.21), NLNK: 39.08 (+1.36), JUNO: 39.99 (+2.71), REGN: 400.12 (+6.07), MYGN: 36.50 (+0.28), PFE: 31.42 (-0.03), IMGN: 5.90 (+0.13), AMGN: 160.67 (+3.15), GSK: 42.85 (+0.11), BMY: 59.15 (-0.01), BLRX: 1.68 (-0.01), OREX: 5.98 (+0.01), DVA: 76.06 (+0.07), BLCM: 19.30 (+0.18), CBST: 100.29 (-0.09), GILD: 91.29 (+1.84), GERN: 3.06 (+0.05), MRK: 57.46 (+0.25), NVS: 93.91 (+0.66)
The Best Healthcare Stocks of 2014: Which Is Our Favorite for 2015?
Todd Campbell, The Motley Fool - Motley Fool - Fri Dec 19, 6:44AM CST
From Medicaid expansion to cancer drugs to minimally invasive treatment for heart disease, Industry Focus looks at the 10 top performers among large-cap healthcare stocks in 2014. There were some surprises on the list this year, with strong showings...
AGN: 210.12 (+0.95), MDVN: 99.23 (+1.23), CNC: 105.96 (+1.03), JNJ: 104.59 (+0.31), VRX: 140.33 (-0.22), ACT: 254.20 (-1.68), EW: 130.75 (+1.17), SNY: 46.35 (+0.50), REGN: 400.12 (+6.07)
Medivation Announces Participation at Upcoming Investor Conference
Marketwired - Wed Dec 17, 3:10PM CST
Medivation, Inc. (NASDAQ: MDVN) today announced that it will present at the following conference:
MDVN: 99.23 (+1.23)
Medivation Poised To Expand As Xtandi Shows Efficacy In Advanced Triple Negative Breast Cancer
Stock Doctor - Seeking Alpha - Wed Dec 17, 7:41AM CST
I last wrote about Medivation (NASDAQ: MDVN ) in July describing why investors should buy the stock ahead of the FDA's decision to expand the use of Xtandi in pre-chemotherapy prostate cancer. As anticipated, the FDA approved the drug's label...
MDVN: 99.23 (+1.23)
4 Top Ranked Biotech Stocks that Beat the Market in 2014 - Analyst Blog
Arpita Dutt - Zacks Investment Research - Tue Dec 16, 10:26AM CST
Despite the sell-off in late March, the biotech sector bounced back thanks to important product approvals, mergers and acquisitions, licensing agreements and strong performances.
MDVN: 99.23 (+1.23), OREX: 5.98 (+0.01), ENDP: 72.10 (+0.34), BMRN: 88.18 (+0.89), CBST: 100.29 (-0.09), GILD: 91.29 (+1.84), GERN: 3.06 (+0.05), AUXL: 34.40 (+0.18), AMGN: 160.67 (+3.15), MNKD: 5.68 (+0.18), CELG: 109.60 (+3.48)
Astellas-Medivation Reveal Data on Xtandi for Breast Cancer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 15, 2:00PM CST
Astellas Pharma Inc. (ALPMY) and Medivation announced the presentation of stage I and preliminary stage II data from a phase II study on Xtandi triple negative breast cancer.
MDVN: 99.23 (+1.23), LCI: 42.29 (+1.79), SCMP: 13.75 (+0.44)
Top Healthcare Stocks for 2014
Todd Campbell, The Motley Fool - Motley Fool - Sun Dec 14, 10:03AM CST
Source: Flickr user Tax Credits . This past year has been a great one for healthcare investors -- the S&P healthcare index ETF offered double the return of the S&P 500. Biotechnology stocks dominated the list of the 10 top-performing...
MNK: 97.84 (-0.29), MDVN: 99.23 (+1.23), CNC: 105.96 (+1.03), AGN: 210.12 (+0.95), VRTX: 115.15 (+1.40), ALNY: 93.52 (+0.97), EW: 130.75 (+1.17), ILMN: 186.22 (+2.72), SNY: 46.35 (+0.50), REGN: 400.12 (+6.07), PBYI: 189.96 (+0.12)
Data Presented From Phase 2 Study of Enzalutamide in Advanced Androgen-Receptor Positive, Triple-Negative Breast Cancer
Marketwired - Fri Dec 12, 5:00PM CST
Medivation, Inc. (NASDAQ: MDVN) and Astellas Pharma Inc. (Tokyo: 4503), announced today the presentation of Stage 1 and preliminary Stage 2 data from a Phase 2 study evaluating the use of enzalutamide as a single agent for the treatment of advanced androgen receptor positive (AR+), triple negative breast cancer (TNBC). Data was presented at the 37th Annual San Antonio Breast Cancer Symposium.
MDVN: 99.23 (+1.23)
Phase 3 PREVAIL Trial Named Clinical Advance of the Year by SCRIP
Marketwired - Wed Dec 10, 3:10PM CST
Medivation, Inc. (NASDAQ: MDVN) and Astellas Pharma Inc. (TSE: 4503) today announced that PREVAIL, the global Phase 3 trial of enzalutamide in metastatic castration-resistant prostate cancer (CRPC), was named the Clinical Advance of the Year by SCRIP, a leading pharmaceutical industry publication.
MDVN: 99.23 (+1.23)
Medivation Set to Possibly Rebound After Yesterday's Selloff of 2.92%
Comtex SmarTrend(R) - Tue Dec 09, 4:33PM CST
Medivation (NASDAQ:MDVN) traded in a range yesterday that spanned from a low of $109.02 to a high of $113.35. Yesterday, the shares fell 2.9%, which took the trading range below the 3-day low of $110.13 on volume of 1.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
MDVN: 99.23 (+1.23)